人工智能在骨髓剂量学与个体化放射性配体治疗中的未来展望
该综述探讨放射性配体治疗中骨髓与血液剂量学的人工智能应用前景,包括提高剂量学准确性、早期识别血液学风险因素及实现适应性治疗计划,并借鉴邻近学科经验提出未来方向,展望人工智能辅助的预测性剂量学结合临床参数推动真正个体化诊疗。
要点
- 放射性配体治疗可能伴发贫血、淋巴细胞减少或血小板减少等血液学副作用。
- 人工智能方法(特别是机器学习与深度学习算法)可能提高骨髓与血液剂量学准确性。
- 未来预期人工智能辅助的预测性剂量学结合临床参数可推动放射性配体治疗的真正个体化诊疗。
核心结论
- 未来预期人工智能辅助的预测性剂量学结合临床参数,可为放射性配体治疗中真正个体化的诊疗铺平道路。
研究设计与样本
- 本文为综述,旨在概述将人工智能方法整合到核医学剂量学领域的新兴机会。
主要发现
- 人工智能方法(尤其是机器学习与深度学习算法)可能提高骨髓和血液剂量学的准确性。
- 人工智能方法可能实现潜在血液学风险因素的早期识别,并支持适应性治疗计划。
- 综述列举了邻近学科中可转化至核医学实践的成功案例,并提供了未来方向的概念性建议。
局限性
- 优化患者管理和基于预测不良事件风险因素的患者选择,并建立在可靠剂量-效应关系之上,仍是尚未满足的需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radioligand therapy is an emerging and effective treatment option for various types of malignancies, but may be intricately linked to hematological side effects such as anemia, lymphopenia or thrombocytopenia. The safety and efficacy of novel theranostic agents, targeting increasingly complex targets, can be well served by comprehensive dosimetry. However, optimization in patient management and patient selection based on risk-factors predicting adverse events and built upon reliable dose-response relations is still an open demand. In this context, artificial intelligence methods, especially machine learning and deep learning algorithms, may play a crucial role. This review provides an overview of upcoming opportunities for integrating artificial intelligence methods into the field of dosimetry in nuclear medicine by improving bone marrow and blood dosimetry accuracy, enabling early identification of potential hematological risk-factors, and allowing for adaptive treatment planning. It will further exemplify inspirational success stories from neighboring disciplines that may be translated to nuclear medicine practices, and will provide conceptual suggestions for future directions. In the future, we expect artificial intelligence-assisted (predictive) dosimetry combined with clinical parameters to pave the way towards truly personalized theranostics in radioligand therapy.
引用
- Moraitis A, Küper A, Tran-Gia J, et al. Future Perspectives of Artificial Intelligence in Bone Marrow Dosimetry and Individualized Radioligand Therapy. Semin Nucl Med. 2024. PMID: 39013673. doi:10.1053/j.semnuclmed.2024.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。